OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern
Erika Rudi, Pablo Martín Aispuro, Eugenia Zurita, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Erika Rudi, Pablo Martín Aispuro, Eugenia Zurita, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Showing 8 citing articles:
A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigens
Simon Joubert, Matthew Stuible, Simon Lord‐Dufour, et al.
Biotechnology and Bioengineering (2023) Vol. 120, Iss. 7, pp. 1746-1761
Open Access | Times Cited: 23
Simon Joubert, Matthew Stuible, Simon Lord‐Dufour, et al.
Biotechnology and Bioengineering (2023) Vol. 120, Iss. 7, pp. 1746-1761
Open Access | Times Cited: 23
Outer membrane vesicles derived from Bordetella pertussis are potent adjuvant that drive Th1-biased response
Bernarda Pschunder, Lucia Locati, Oriana López, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Bernarda Pschunder, Lucia Locati, Oriana López, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Correction to “Recombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2” [Vaccine 2023 Sep 22 41(41) 6025–6035. Doi: 10.1016/j.vaccine.2023.08.054]
S. Chiba, Peter Halfmann, Shun Iida, et al.
Vaccine (2025) Vol. 52, pp. 126880-126880
Closed Access
S. Chiba, Peter Halfmann, Shun Iida, et al.
Vaccine (2025) Vol. 52, pp. 126880-126880
Closed Access
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Dual-Domain Reporter Approach for Multiplex Identification of Major SARS-CoV-2 Variants of Concern in a Microarray-Based Assay
Francesco Damin, Silvia Galbiati, Nicola Clementi, et al.
Biosensors (2023) Vol. 13, Iss. 2, pp. 269-269
Open Access | Times Cited: 1
Francesco Damin, Silvia Galbiati, Nicola Clementi, et al.
Biosensors (2023) Vol. 13, Iss. 2, pp. 269-269
Open Access | Times Cited: 1
Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2
S. Chiba, Peter Halfmann, Shun Iida, et al.
Vaccine (2023) Vol. 41, Iss. 41, pp. 6025-6035
Open Access
S. Chiba, Peter Halfmann, Shun Iida, et al.
Vaccine (2023) Vol. 41, Iss. 41, pp. 6025-6035
Open Access
Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron
Daniela Bottero, Erika Rudi, Pablo Martín Aispuro, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Daniela Bottero, Erika Rudi, Pablo Martín Aispuro, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron
Daniela Bottero, Erika Rudi, Pablo Martín Aispuro, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access
Daniela Bottero, Erika Rudi, Pablo Martín Aispuro, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access
